BREAKING NEWS: Radicava (edaravone) Approved by FDA

BREAKING NEWS:
The US Food and Drug Administration has approved Radicava (edaravone) to treat people with ALS in the United States. 

This is important news for the ALS community. Radicava (edaravone) was approved today by the FDA to treat people with ALS. “After learning about the use of edaravone to treat ALS in Japan, we rapidly engaged with the drug developer about filing a marketing application in the United States,” said Eric Bastings, M.D., deputy director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “This is the first new treatment approved by the FDA for ALS in many years, and we are pleased that people with ALS will now have an additional option.”

We at the ALS Hope Foundation would like to congratulate MT Pharma America on this latest development. The neurologists at the MDA/ALS Center of Hope clinic are looking forward to having a new treatment option. For more information on Radicava, please visit their website, www.radicava.com, or read the press release.

We also want to thank YOU for donating and advocating for people with ALS and their families, not only during ALS Awareness Month, but everyday. You helped make this possible! Thank you for your support!